EQS-News: Springer Nature reports strong growth in the first half of 2025 and raises full-year guidance

Springer Nature AG & Co. KGaA · ISIN: DE000SPG1003 · EQS - Company News

Country: Germany · Primary market: Germany · EQS NID: 2183086

EQS-News: Springer Nature AG & Co. KGaA / Key word(s): Half Year Results
Springer Nature reports strong growth in the first half of 2025 and raises full-year guidance

13.08.2025 / 07:00 CET/CEST
The issuer is solely responsible for the content of this announcement.

PRESS RELEASE

Springer Nature reports strong growth in the first half of 2025 and raises full-year guidance

Strong performance with 6% underlying¹ revenue growth and 10% underlying¹ adjusted operating profit growth (AOP)
Research is key growth driver (7%); Journals outgrowing the market
Free cash flow up 51% to €204 million; leverage ratio reduced to 1.9x
Continued progress on AI as a strategic priority
Full-year 2025 guidance raised for both revenue and AOP

Berlin, 13 August 2025

Springer Nature, a leading global science publisher, today announced strong results for the first half of 2025. On an underlying¹ basis, group revenue rose by 6% and adjusted operating profit (AOP) by 10%. First-half revenue increased to €926 million and AOP to €241 million, supported by a favourable revenue mix. Growth was driven by the Research segment. Nearly all 2025 contract renewals have been completed and continued high submission volumes to the Journals portfolio have driven further above-market publication growth. Reflecting this strong performance, the company has raised its full-year guidance for both revenue and AOP.

Frank Vrancken Peeters, CEO of Springer Nature, said: “In the year Springer Nature celebrates its 10^th anniversary we’re publishing more high-quality science than ever and continuing to enhance our services for authors and researchers — something we’re truly proud of. This strong first half performance, which outpaces the market, reflects our leadership in open access and the impact of our long-term technology investments.”

Research, the company’s largest segment, reported revenue of €731 million. The segment contributed most significantly to operating performance, with underlying¹ revenue growth of 7%. This was driven by the Journals portfolio and the continued momentum in open access (OA) globally. The number of published articles rose by approximately 10% across the whole portfolio and around 25% in Full Open Access (FOA) journals.

By mid-year, Springer Nature had completed nearly all its 2025 contract renewals and signed 17 transformative agreements to further accelerate the shift to OA. The company also launched 24 new journals and is preparing two additional Nature titles for early 2026. Digital book formats continued to grow, offsetting declines in print, with digital now representing about 70% of book sales.

The company continued to invest in a range of initiatives to support growth and ensure research integrity. It also maintained a focus on developing AI tools to transform the publication process, provide more value to communities and create new revenue streams. Among these tools is the new AI-powered Nature Research Assistant, which recently entered public beta testing. It is designed to make some of the most time-consuming parts of the research process, including reading and writing, quicker and easier.

In Health, revenue was €90 million. The underlying¹ revenue growth of 4% was supported by strong performance in scientific affairs services following a refocus of the international pharma division and solid performance in the Dutch events and books business. Education revenue amounted to €105 million, with underlying¹ revenue growth of 3% driven by strong performance in Curriculum, particularly in Latin America.

Free cash flow rose by €69 million to €204 million in the first half of the year, largely due to the improved operating performance and lower interest payments. The company further reduced financial leverage to 1.9x net debt to adjusted EBITDA, versus its target range of 1.5x to 2.0x. The adjusted net result in the first half of 2025 was €166 million, up from €113 million in the same period last year.

As a result of its strong performance, Springer Nature has raised its guidance for 2025. The company now expects revenue to be in the range of €1,930 million to €1,960 million and AOP between €540 million to €560 million. This guidance is based on the underlying performance, excluding effects from year-on-year changes in foreign currencies and portfolio.

Alexandra Dambeck, the company’s CFO, said: “Our updated guidance reflects the strong momentum we have seen in the first half of the year and the continued strength of our portfolio. We are also making clear progress in strengthening our balance sheet, supported by robust free cash flow, which gives us the flexibility to pursue sustainable growth and deliver value to our stakeholders.”

Springer Nature financial KPI H1 2025

Performance indicators at a glance

in € million	H1 2025	H1 2024	Change	Underlying change
Revenue	925.9	883.1	4.8%	6.2%
Adjusted operating profit	240.6	225.3	6.8%	9.8%
Free cash flow	203.8	134.9	68.9
Financial leverage^a,b	1.9x	2.3x

aFinancial leverage of 2.3x refers to 31 December 2024.
b Financial leverage is defined as net financial debt divided by the past 12 months’ adjusted EBITDA. Adjusted EBITDA is defined as EBITDA before capital gains/losses from the acquisition/disposal of businesses/investments and exceptional items. Net financial debt is defined as interest-bearing loans and borrowings including lease liabilities minus cash and cash equivalents.

Notes relating to forward-looking statements
This document contains statements about the future business development and strategic direction of the company. The forward-looking statements are based on management’s current expectations and assumptions. They are subject to certain risks and fluctuations as described in other publications, in particular in the risk and opportunities section of the combined management report. If these expectations and assumptions do not apply or if unforeseen risks arise, the actual course of business may differ significantly from the expected developments. We therefore assume no liability for the accuracy of these forecasts.

About Springer Nature
Springer Nature is one of the leading publishers of research in the world. We publish the largest number of journals and books and are a pioneer in open research. Through our leading brands, trusted for more than 180 years, we provide technology-enabled products, platforms and services that help researchers to uncover new ideas and share their discoveries, health professionals to stay at the forefront of medical science, and educators to advance learning. We are proud to be part of progress, working together with the communities we serve to share knowledge and bring greater understanding to the world. For more information, please visit about.springernature.com and @SpringerNature.

Contact

Cornelius Rahn | Springer Nature | Communications and Corporate Affairs
tel +49 151 1563 7515 | cornelius.rahn@springernature.com

¹Underlying change excludes effects from year-on-year changes in foreign currencies and portfolio.

13.08.2025 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group.
The issuer is solely responsible for the content of this announcement.

The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.eqs-news.com

Language:	English
Company:	Springer Nature AG & Co. KGaA
	Heidelberger Platz 3
	14197 Berlin
	Germany
Phone:	+49 (0)30 - 82787 - 0
E-mail:	ir@springernature.com
Internet:	www.springernature.com
ISIN:	DE000SPG1003
WKN:	SPG100
Indices:	SDAX
Listed:	Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Munich, Stuttgart, Tradegate Exchange; Vienna Stock Exchange (Vienna MTF)
EQS News ID:	2183086


End of News	EQS News Service

2183086 13.08.2025 CET/CEST

More Research

Company related KPIs

Boersengefluester.de (BGFL) provides an overview of the key figures on sales, earnings, cash flow and dividends to help you better assess the fundamental development of the respective companies. All information is entered manually in our database - the source is the respective annual reports. All estimates for future figures are provided by BGFL.

The most important financial data at a glance
	2019	2020	2021	2022	2023	2024	2025e
Sales¹	0,00	1.626,70	1.700,90	1.821,80	1.853,00	1.847,10	1.950,00
EBITDA^1,2	0,00	592,30	642,00	679,50	746,80	678,50	760,00
EBITDA-Margin³	0,00	36,41	37,75	37,30	40,30	36,73	38,97
EBIT^1,4	0,00	264,70	307,50	386,90	461,70	394,60	550,00
EBIT-Margin⁵	0,00	16,27	18,08	21,24	24,92	21,36	28,21
Net Profit (Loss)¹	0,00	28,00	-9,00	199,50	15,70	69,00	91,00
Net-Margin⁶	0,00	1,72	-0,53	10,95	0,85	3,74	4,67
Cashflow^1,7	0,00	570,20	610,80	504,80	491,90	531,20	540,00
Earnings per share⁸	0,23	0,13	-0,05	1,00	0,08	0,34	0,45
Dividend per share⁸	0,00	0,00	0,00	0,00	0,00	0,13	0,15

Quelle: boersengefluester.de and Company information

Explanation

¹ in Mio. Euro; ² EBITDA = Earnings before interest, taxes, depreciation and amortisation; ³ EBITDA in relation to sales; ⁴ EBIT = Earnings before interest and taxes; ⁵ EBIT in relation to sales; ⁶ Net profit (-loss) in relation to sales; ⁷ Cashflow from operations; ⁸ in Euro; Source: boersengefluester.de

Auditor: Ernst & Young

Company Snapshot

All relevant valuation ratios, dates and other investor information on your share at a glance. Good to know: All data comes from boersengefluester.de and is updated daily. This means you are always up to date. You can get brief explanations of the key figures by moving the cursor or mouse over the relevant field.

INVESTOR-INFORMATION
©boersengefluester.de
Springer Nature
WKN	ISIN	Legal Type	Marketcap	IPO	Recommendation	Plus Code
SPG100	DE000SPG1003	AG & Co. KGaA	3.829,87 Mio €	04.10.2024		9F4MF8H6+CP

* * *

PE 2026e	PE 10Y-Ø	BGFL-Ratio	Shiller-PE	PB	PCF	KUV
39,10	42,58	0,92	186,02	2,15	7,21	2,07

Dividends

Dividend '2023 in €	Dividend '2024 in €	Dividend '2025e in €	Div.-Yield '2025e in %
0,00	0,13	0,15	0,78%

Financial calendar

Annual General Meeting	Q1-figures	Q2-figures	Q3-figures	Annual press conference
05.06.2025	13.05.2025	13.08.2025	12.11.2025	31.03.2025

Performance

Distance 60-days-line	Distance 200-days-line	Performance YtD	Performance 52 weeks	IPO	Last Price (EoD) -3,72% 19,16 € ATH 28,30 €
-13,04%	-7,76%	-29,56%	-25,33%	-14,84%	Last Price (EoD) -3,72% 19,16 € ATH 28,30 €

LEI: 549300UMNC43HQB3JA96

Social media-channel

Advertising is an important revenue channel for us. But we understand, that sometimes it becomes annoying. If you want to reduce the number of shown ADs just simply login to your useraccount and manage the settings from there. As registered user you get even more benefits.

EQS-News: Springer Nature reports strong growth in the first half of 2025 and raises full-year guidance

Quick Links

Network

Partner

Contact

EQS-News: Springer Nature reports strong growth in the first half of 2025 and raises full-year guidance

Would you like to see fewer adverts? Simply register for a user account. Registration is free and significantly reduces the number of adverts.

Quick Links

Network

Partner

Contact